UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on ...
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, ...
Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by ...
Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...
The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.
National Institutes of Health (NIH) scientists and their colleagues report that a single dose of a broadly neutralizing antibody (bnAb) administered prior to virus exposure protects macaques from ...
Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback